AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

A host of corporate developments—from regulatory actions and major contracts to earnings, acquisitions, and management ...

The yields on UK ten year bonds rose sharply on Wednesday as Keir Starmer failed to guarantee the job of chancellor Rachel ...

The FTSE 100 and European stocks were jittery on Friday, moving lower as US markets were closed for 4 July, while investors look to movement in US tax and tariff policy for clues ...

The FTSE 100 index closed up 48.51 points, 0.6%, at 8,823.20. The FTSE 250 jumped 250.09 points, 1.2%, at 21,702.58, and the ...

The FTSE 100 and sterling rallied, while the bond market calmed on Thursday as Keir Starmer supported his chancellor, reassuring markets that a change at the Treasury wasn't on the cards. The FTSE 100 ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...

AstraZeneca, which has a market value of about 156 billion pounds ($213 billion), declined to comment. The company has for years criticised the UK business investment climate.

Trading in AstraZeneca 's (AZN -0.46%) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange.

This is MoneyAstraZeneca boost as EU approves cancer drug By EMILY HAWKINS Updated: 16:50 EDT, 4 July 2025 ...